Recon: Sanofi to acquire Translate Bio for $3.2B; BMS withdraws Istodax indication after confirmatory trial fails
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy